CureVac Shareholders Face a Critical Deadline

For remaining investors in CureVac, the clock is ticking down to a decisive moment. The company’s journey as an independent entity is concluding, following BioNTech’s successful acquisition of a controlling stake. Shareholders who have not yet accepted the exchange offer must now act swiftly, as the expiration of the current acceptance window could lead to significant disadvantages, including the potential delisting of the stock.

The takeover is structured as a pure share-for-share exchange. Under the agreed terms, CureVac stockholders will receive 0.05363 BioNTech American Depositary Shares (ADS) for each of their existing CureVac shares. This fixed ratio effectively caps any further upside for CureVac’s stock, directly Read more...